#cardiotox
MADRID
12 - 13 NOVEMBER 2026 | Meeting Place Castellana, 81
MADRID
12 - 13 NOVEMBER 2026
Meeting Place Castellana, 81

More information soon

Cardiotox Programme

12-13 November 2026

Cardiotox Programme

12-13 November 2026​

II Jornada Cardiotox - SEMERGEN

12 November 2026

More info
12 nov
13 nov
Filtro
09:00 - 09:05
Inauguration
09:05 - 09:35
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
09:35 - 10:30
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
11:00 - 11:45
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
11:45 - 12:15
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12:15 - 13:15
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
13:50 - 14:00
Inauguración
14:00 - 14:45
Riesgo cardiovascular en pacientes con cáncer
14:45 - 15:30
Prevención cardiovascular más allá de la cardiotoxicidad
15:20 - 16:15
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
16:00 - 16:45
Anticoagulación y manejo de arritmias en el paciente con cáncer
16:15 - 17:00
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
16:45 - 17:15
Ejercicio y dieta, en pacientes con cáncer: guía rápida para Atención Primaria
17:00 - 18:00
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
17:15 - 17:45
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
17:30 - 19:00
TUTORIALS / SATELLITE SYMPOSIUM
17:45 - 17:55
Cierre
08:30 - 09:10
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
09:10 - 09:50
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
09:50 - 10:30
GRACE DIGITAL MONITORING ACADEMY Remote monitoring in cardio-oncology: ready for implementation or still a work in progress?
11:00 - 12:00
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
12:00 - 12:50
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
12:50 - 13:30
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13:30 - 14:15
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
16:00 - 17:00
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
17:00 - 17:45
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
17:15 - 17:30
CLOSING REMARKS
Tipo de sesión: SESSION
Inauguration
12 Nov
Main auditorium
9:00 - 9:05
Modera
Teresa López Fernández
Raúl Córdoba Mascuñano
Álvaro Pinto Marín
Isabel Rodríguez Rodríguez
Tipo de sesión: SESSION
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 Nov
Main auditorium
9:05 - 9:35
Modera
Javier de Castro Carpeño
Raúl Córdoba Mascuñano
Isabel Rodríguez Rodríguez
Cardio-oncology 2026: key advances for the clinic
Teresa López Fernández
Proton therapy: is the heart still at risk?
Marianne Aznar
Discussion
Tipo de sesión: FROM BENCH TO BEDSIDE
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 Nov
Main auditorium
9:35 - 10:30
Modera
Carlo Gabriele Tocchetti
Virginia Calvo de Juan
Mechanisms of ICI-related myotoxicity
Pilar Martín Fernández
ICI myotoxicity: from mechanisms to targeted treatment
Joe-Eli Salem
Translational biomarkers in immune-related cardiotoxicity: from inflammatory cells to risk stratification
María Rosaria Galdiero
T cell–based cancer therapies and associated cardiac irAEs
Lorenz Lehmann
Discussion
Tipo de sesión: MEET THE EXPERTS
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 Nov
Main auditorium
11:00 - 11:45
Modera
Virginia Calvo de Juan
Pedro Moliner Borja
ICI rechallenge after myocarditis: time for reassessment?
Joe-Eli Salem
EGFR-targeted therapies: cardiovascular toxicity and monitoring
Oliver Higuera Gómez
ALK inhibitors: practical surveillance and metabolic management
Dolores Isla Casado
Discussion
Tipo de sesión: IN FOCUS
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 Nov
Main auditorium
11:45 - 12:15
Modera
Valentín García Gutiérrez
Marta Fanlo Maresma
Panel discussion
Juan Pedro Justel
Pilar Agudo Quílez
Raquel de Paz Arias
Tipo de sesión: SESSION
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 Nov
Main auditorium
12:15 - 13:15
Modera
Victoria Delgado García
Pilar Zamora Auñón
How imaging in cardio-oncology has changed over the last decade
Dolores Mesa
GLS drop: treat or observe?
Belén Terol Espinosa de los Monteros
CMR: When does it alter therapy?
Rocío Eiros Bachiller
CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls?
Chiara Bucciarelli-Ducci
Asymptomatic ASCVD in cancer survivorship: what next?
Inés García Lunar
Discussion
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Inauguración
12 Nov
Room 1
13:50 - 14:00
Modera
Juan Pedro Justel
Sergio Cinza Sanjurjo
Vicente Pallarés Carratalá
Teresa López Fernández
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Riesgo cardiovascular en pacientes con cáncer
12 Nov
Room 1
14:00 - 14:45
Modera
Leticia Ruiz-Giménez
Milagros Pedreira
Riesgo cardiovascular basal: qué identificar
Juan Pedro Justel
Alertas durante el tratamiento: cuándo actuar y cuándo derivar
Sergio Cinza Sanjurjo
Enfermedad venosa y cáncer: el riesgo cardiovascular olvidado
Cristina Feijoo Cano
Discusión
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Prevención cardiovascular más allá de la cardiotoxicidad
12 Nov
Room 1
14:45 - 15:30
Modera
Regina Dalmau
Raquel de Paz Arias
Aterosclerosis acelerada y daño vascular asociado al tratamiento oncológico
Marta Fanlo Maresma
Dislipemia en cáncer: ¿mismos objetivos que en población general?
José Luis Díaz Díaz
Hipertensión asociada al tratamiento oncológico: objetivos realistas y seguros
Milagros Pedreira
Discusión
Tipo de sesión: FROM BENCH TO BEDSIDE
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 Nov
Main auditorium
15:20 - 16:15
Modera
Lorenz Lehmann
Inés García Lunar
Anthracycline cardiotoxicity: molecular mechanisms that inform prevention
Alessandra Ghigo
Exercise in CTRCD: mechanistic rationale and treatment windows
Carlo Gabriele Tocchetti
Neurohormonal inhibition in CTRCD: preclinical and clinical evidence
Pietro Ameri
Reversible vs irreversible CTRCD: biological continuum or distinct entities?
Dimitrios Farmakis
Discussion
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 Nov
Room 1
16:00 - 16:45
Modera
Vicente Pallarés Carratalá
Juan Pedro Justel
Fibrilación auricular en cáncer activo ¿Cuándo pensar en control de ritmo?
Cristina Mitroi
Anticoagulación en CHA₂DS₂-VA bajo y en trombocitopenia
Ana Martín García
Alertas ECG durante el tratamiento oncológico
Sergio Cinza Sanjurjo
Discusión
Tipo de sesión: SESSION
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 Nov
Main auditorium
16:15 - 17:00
Modera
Chiara Bucciarelli-Ducci
Clinical case presentation: why imaging workflows are now a bottleneck in cardio-oncology
Silvia Valbuena
Echocardiography workflows: prioritisation, standardisation and AI implementation
Victoria Delgado García
CMR workflows: selecting the right patients and delivering actionable answers
Santo Dellegrottaglie
Panel discussion: what should an efficient cardio-oncology imaging pathway look like?
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Ejercicio y dieta, en pacientes con cáncer: guía rápida para Atención Primaria
12 Nov
Room 1
16:45 - 17:15
Modera
Sergio Cinza Sanjurjo
Ejercicio y dieta, en pacientes con cáncer: guía rápida para Atención Primaria
Tipo de sesión: CLINICAL CASE FORUM
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 Nov
Main auditorium
17:00 - 18:00
Modera
Eduardo Zatarain
Pietro Ameri
Antonia Sambola
ICI-myotoxicity: early signals and grey zones
Jorge Álvarez Troncoso
Acute coronary syndrome during cancer treatment
Pedro Moliner Borja
Cardiovascular complications of CRS in CAR-T therapy
Annamaria Brioli
Acute pulmonary embolism in cancer: when to escalate
Sandra Rosillo Rodríguez
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 Nov
Room 1
17:15 - 17:45
Modera
Pilar Mazón Ramos
Raquel de Paz Arias
Diego Jiménez Bou
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
Vicente Pallarés Carratalá
Tipo de sesión: SYMPOSIUM
TUTORIALS / SATELLITE SYMPOSIUM
12 Nov
17:30 - 19:00
Tipo de sesión: II Jornada CardioTox-SEMERGEN
Cierre
12 Nov
Room 1
17:45 - 17:55
Modera
Juan Pedro Justel
Sergio Cinza Sanjurjo
Vicente Pallarés Carratalá
Teresa López Fernández
Tipo de sesión: SYMPOSIUM
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 Nov
Main auditorium
8:30 - 9:10
Modera
Peter van der Meer
Cristina Mitroi
Cardiovascular risk with immunotherapy-based combinations
Diego Jiménez Bou
Endocrine and targeted therapies in breast cancer: the unresolved long-term cardiovascular burden
Jutta Bergler-Klein
Biomarkers for risk stratification and long-term surveillance
Daniela Cardinale
Discussion
Tipo de sesión: IN FOCUS
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 Nov
Main auditorium
9:10 - 9:50
Modera
Chiara Bucciarelli-Ducci
Dimitrios Farmakis
Clinical and imaging red flags
Rocío Eiros Bachiller
ATTR cardiac amyloidosis: recent therapeutic advances
Peter van der Meer
AL cardiac amyloidosis: emerging treatment strategies and cardiac outcomes
Annamaria Brioli
Discussion
Tipo de sesión: SYMPOSIUM
GRACE DIGITAL MONITORING ACADEMY Remote monitoring in cardio-oncology: ready for implementation or still a work in progress?
13 Nov
Main auditorium
9:50 - 10:30
Introduction
Remote monitoring during cancer care: workload reducer or complexity amplifier?
Remote monitoring during cancer care: who really needs it?
Discussion
Tipo de sesión: CLINICAL CASE FORUM
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 Nov
Main auditorium
11:00 - 12:00
Modera
Pilar Zamora Auñón
Victoria Delgado García
Antonia Sambola
Fluoropyrimidine-associated chest pain: acute management and next steps
Cristina Contreras Lorenzo
Severe aortic stenosis in active cancer: timing TAVI and competing clinical priorities
Amparo Martínez Monzonis
When anticoagulation leads to bleeding: what to do and when to act?
Cristina Pascual Izquierdo
Obesity in cancer care: ignore or treat from day one?
Almudena Castro Conde
Tipo de sesión: FROM BENCH TO BEDSIDE
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 Nov
Main auditorium
12:00 - 12:50
Modera
Cristina Mitroi
Álvaro Pinto Marín
CHIP as a cardiovascular risk modifier: what matters in cardio-oncology?
José Javier Fuster Ortuño
CHIP in lymphoma: biological links and implications for cardiac injury
Miguel Canales
TTN truncating variants before anthracycline therapy: proceed, modify or protect?
Juan Caro Códon
Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis
Rebeca Lorca Gutiérrez
Discussion
Tipo de sesión: MEET THE EXPERTS
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 Nov
Main auditorium
12:50 - 13:30
Modera
Álvaro Pinto Marín
Sergio Cinza Sanjurjo
Cardiovascular adverse events with tyrosine-kinase inhibitors for renal cancer
Guillermo de Velasco de Rueda
Hormone therapy for prostate cancer and cardiovascular toxicity
Natalia Vidal Cassinello
Pre-treatment assessments in patients with prostate cancer
Estefanía Linares Espinos
Discussion
Tipo de sesión: IN FOCUS
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 Nov
Main auditorium
13:30 - 14:15
Modera
Raúl Córdoba Mascuñano
Rebeca Lorca Gutiérrez
Real-world evidence: beyond clinical trials
Alicia Aguirre
Finite vs continuous treatment: cardiovascular risk after treatment discontinuation
Lucrecia Yáñez
Non-covalent BTK inhibitors: a new drug class with a favourable cardiovascular safety profile
José Ángel Hernández Rivas
Hospital Universitario Infanta Leonor, Madrid
Discussion
Tipo de sesión: CLINICAL CASE FORUM
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 Nov
Main auditorium
16:00 - 17:00
Modera
Vicente Pallarés Carratalá
Ana Martín García
Albuminuria during VEGF inhibition: marker or mandate to act
Pilar Mazón Ramos
Permissive cardiotoxicity: LVEF-led or context-led decision-making?
Eduardo Zatarain
Myocardial injury in acute leukaemia: a triple-hit of host, disease, and treatment
Gabriela Rodríguez Macías
CV surveillance after HSCT: defining who is truly high-risk
Irene Sánchez Vadillo
Tipo de sesión: SYMPOSIUM
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
13 Nov
Main auditorium
17:00 - 17:45
Modera
Raúl Córdoba Mascuñano
Teresa López Fernández
Translational research priorities in cardio-oncology
Borja Ibáñez Cabeza
Cardio-oncology roadmap: from trials and real-world data to future guidelines
Alexander Lyon
Discussion
Tipo de sesión: SESSION
CLOSING REMARKS
13 Nov
Main auditorium
17:15 - 17:30
Teresa López Fernández
Inauguration
12 nov
Main auditorium
9:00 - 9:05
Modera
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 nov
Main auditorium
9:05 - 9:35
Interviene en:
Cardio-oncology 2026: key advances for the clinic
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
13 nov
Main auditorium
17:00 - 17:45
Modera
Marianne Aznar
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 nov
Main auditorium
9:05 - 9:35
Interviene en:
Proton therapy: is the heart still at risk?
Pilar Martín Fernández
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Interviene en:
Mechanisms of ICI-related myotoxicity
Joe-Eli Salem
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Interviene en:
ICI myotoxicity: from mechanisms to targeted treatment
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 nov
Main auditorium
11:00 - 11:45
Interviene en:
ICI rechallenge after myocarditis: time for reassessment?
María Rosaria Galdiero
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Interviene en:
Translational biomarkers in immune-related cardiotoxicity: from inflammatory cells to risk stratification
Lorenz Lehmann
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Interviene en:
T cell–based cancer therapies and associated cardiac irAEs
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Modera
Oliver Higuera Gómez
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 nov
Main auditorium
11:00 - 11:45
Interviene en:
EGFR-targeted therapies: cardiovascular toxicity and monitoring
Dolores Isla Casado
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 nov
Main auditorium
11:00 - 11:45
Interviene en:
ALK inhibitors: practical surveillance and metabolic management
Pilar Agudo Quílez
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Interviene en:
Panel discussion
Juan Pedro Justel
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Interviene en:
Panel discussion
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Interviene en:
Riesgo cardiovascular basal: qué identificar
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Modera
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
Belén Terol Espinosa de los Monteros
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
GLS drop: treat or observe?
Rocío Eiros Bachiller
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
CMR: When does it alter therapy?
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Interviene en:
Clinical and imaging red flags
Chiara Bucciarelli-Ducci
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls?
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 nov
Main auditorium
16:15 - 17:00
Modera
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Modera
Inés García Lunar
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
Asymptomatic ASCVD in cancer survivorship: what next?
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Modera
Alessandra Ghigo
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Anthracycline cardiotoxicity: molecular mechanisms that inform prevention
Carlo Gabriele Tocchetti
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Modera
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Exercise in CTRCD: mechanistic rationale and treatment windows
Pietro Ameri
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Neurohormonal inhibition in CTRCD: preclinical and clinical evidence
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Modera
Dimitrios Farmakis
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Reversible vs irreversible CTRCD: biological continuum or distinct entities?
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Modera
Jorge Álvarez Troncoso
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Interviene en:
ICI-myotoxicity: early signals and grey zones
Pedro Moliner Borja
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 nov
Main auditorium
11:00 - 11:45
Modera
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Interviene en:
Acute coronary syndrome during cancer treatment
Annamaria Brioli
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Interviene en:
Cardiovascular complications of CRS in CAR-T therapy
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Interviene en:
AL cardiac amyloidosis: emerging treatment strategies and cardiac outcomes
Sandra Rosillo Rodríguez
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Interviene en:
Acute pulmonary embolism in cancer: when to escalate
Jutta Bergler-Klein
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Interviene en:
Endocrine and targeted therapies in breast cancer: the unresolved long-term cardiovascular burden
Daniela Cardinale
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Interviene en:
Biomarkers for risk stratification and long-term surveillance
Peter van der Meer
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Modera
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Interviene en:
ATTR cardiac amyloidosis: recent therapeutic advances
Cristina Contreras Lorenzo
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Interviene en:
Fluoropyrimidine-associated chest pain: acute management and next steps
Amparo Martínez Monzonis
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Interviene en:
Severe aortic stenosis in active cancer: timing TAVI and competing clinical priorities
Cristina Pascual Izquierdo
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Interviene en:
When anticoagulation leads to bleeding: what to do and when to act?
José Javier Fuster Ortuño
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Interviene en:
CHIP as a cardiovascular risk modifier: what matters in cardio-oncology?
Miguel Canales
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Interviene en:
CHIP in lymphoma: biological links and implications for cardiac injury
Juan Caro Códon
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Interviene en:
TTN truncating variants before anthracycline therapy: proceed, modify or protect?
Rebeca Lorca Gutiérrez
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Interviene en:
Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 nov
Main auditorium
13:30 - 14:15
Modera
Guillermo de Velasco de Rueda
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 nov
Main auditorium
12:50 - 13:30
Interviene en:
Cardiovascular adverse events with tyrosine-kinase inhibitors for renal cancer
Natalia Vidal Cassinello
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 nov
Main auditorium
12:50 - 13:30
Interviene en:
Hormone therapy for prostate cancer and cardiovascular toxicity
Estefanía Linares Espinos
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 nov
Main auditorium
12:50 - 13:30
Interviene en:
Pre-treatment assessments in patients with prostate cancer
Pilar Mazón Ramos
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Modera
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Interviene en:
Albuminuria during VEGF inhibition: marker or mandate to act
Eduardo Zatarain
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Modera
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Interviene en:
Permissive cardiotoxicity: LVEF-led or context-led decision-making?
Gabriela Rodríguez Macías
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Interviene en:
Myocardial injury in acute leukaemia: a triple-hit of host, disease, and treatment
Alexander Lyon
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
13 nov
Main auditorium
17:00 - 17:45
Interviene en:
Cardio-oncology roadmap: from trials and real-world data to future guidelines
Borja Ibáñez Cabeza
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
13 nov
Main auditorium
17:00 - 17:45
Interviene en:
Translational research priorities in cardio-oncology
José Ángel Hernández Rivas
Hospital Universitario Infanta Leonor, Madrid
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 nov
Main auditorium
13:30 - 14:15
Interviene en:
Non-covalent BTK inhibitors: a new drug class with a favourable cardiovascular safety profile
Lucrecia Yáñez
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 nov
Main auditorium
13:30 - 14:15
Interviene en:
Finite vs continuous treatment: cardiovascular risk after treatment discontinuation
Sergio Cinza Sanjurjo
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Interviene en:
Alertas durante el tratamiento: cuándo actuar y cuándo derivar
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Interviene en:
Alertas ECG durante el tratamiento oncológico
Ejercicio y dieta, en pacientes con cáncer: guía rápida para Atención Primaria
12 nov
Room 1
16:45 - 17:15
Modera
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 nov
Main auditorium
12:50 - 13:30
Modera
Marta Fanlo Maresma
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Modera
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Interviene en:
Aterosclerosis acelerada y daño vascular asociado al tratamiento oncológico
Cristina Mitroi
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Interviene en:
Fibrilación auricular en cáncer activo ¿Cuándo pensar en control de ritmo?
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Modera
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Modera
Ana Martín García
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Interviene en:
Anticoagulación en CHA₂DS₂-VA bajo y en trombocitopenia
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Modera
Vicente Pallarés Carratalá
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Modera
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Interviene en:
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Modera
Cristina Feijoo Cano
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Interviene en:
Enfermedad venosa y cáncer: el riesgo cardiovascular olvidado
José Luis Díaz Díaz
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Interviene en:
Dislipemia en cáncer: ¿mismos objetivos que en población general?
Milagros Pedreira
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Modera
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Interviene en:
Hipertensión asociada al tratamiento oncológico: objetivos realistas y seguros
Diego Jiménez Bou
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Modera
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Interviene en:
Cardiovascular risk with immunotherapy-based combinations
Alicia Aguirre
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 nov
Main auditorium
13:30 - 14:15
Interviene en:
Real-world evidence: beyond clinical trials
Dolores Mesa
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
How imaging in cardio-oncology has changed over the last decade
Raquel de Paz Arias
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Interviene en:
Panel discussion
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Modera
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Modera
Victoria Delgado García
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Modera
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 nov
Main auditorium
16:15 - 17:00
Interviene en:
Echocardiography workflows: prioritisation, standardisation and AI implementation
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Modera
Santo Dellegrottaglie
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 nov
Main auditorium
16:15 - 17:00
Interviene en:
CMR workflows: selecting the right patients and delivering actionable answers
Almudena Castro Conde
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Interviene en:
Obesity in cancer care: ignore or treat from day one?
Irene Sánchez Vadillo
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Interviene en:
CV surveillance after HSCT: defining who is truly high-risk
Silvia Valbuena
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 nov
Main auditorium
16:15 - 17:00
Interviene en:
Clinical case presentation: why imaging workflows are now a bottleneck in cardio-oncology
Teresa López Fernández
Inauguration
12 nov
Main auditorium
9:00 - 9:05
Modera
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 nov
Main auditorium
9:05 - 9:35
Interviene en:
Cardio-oncology 2026: key advances for the clinic
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
13 nov
Main auditorium
17:00 - 17:45
Modera
Raúl Córdoba Mascuñano
Inauguration
12 nov
Main auditorium
9:00 - 9:05
Modera
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 nov
Main auditorium
9:05 - 9:35
Modera
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 nov
Main auditorium
13:30 - 14:15
Modera
SYMPOSIUM. Building the roadmap for the next generation of cardio-oncology care
13 nov
Main auditorium
17:00 - 17:45
Modera
Álvaro Pinto Marín
Inauguration
12 nov
Main auditorium
9:00 - 9:05
Modera
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Modera
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 nov
Main auditorium
12:50 - 13:30
Modera
Isabel Rodríguez Rodríguez
Inauguration
12 nov
Main auditorium
9:00 - 9:05
Modera
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 nov
Main auditorium
9:05 - 9:35
Modera
Javier de Castro Carpeño
TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE
12 nov
Main auditorium
9:05 - 9:35
Modera
Carlo Gabriele Tocchetti
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Modera
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Exercise in CTRCD: mechanistic rationale and treatment windows
Virginia Calvo de Juan
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Modera
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 nov
Main auditorium
11:00 - 11:45
Modera
Pedro Moliner Borja
MEET THE EXPERTS. Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance
12 nov
Main auditorium
11:00 - 11:45
Modera
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Interviene en:
Acute coronary syndrome during cancer treatment
Valentín García Gutiérrez
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Modera
Marta Fanlo Maresma
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Modera
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Interviene en:
Aterosclerosis acelerada y daño vascular asociado al tratamiento oncológico
Victoria Delgado García
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Modera
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 nov
Main auditorium
16:15 - 17:00
Interviene en:
Echocardiography workflows: prioritisation, standardisation and AI implementation
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Modera
Pilar Zamora Auñón
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Modera
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Modera
Lorenz Lehmann
FROM BENCH TO BEDSIDE. Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events
12 nov
Main auditorium
9:35 - 10:30
Interviene en:
T cell–based cancer therapies and associated cardiac irAEs
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Modera
Inés García Lunar
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
Asymptomatic ASCVD in cancer survivorship: what next?
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Modera
Eduardo Zatarain
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Modera
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Interviene en:
Permissive cardiotoxicity: LVEF-led or context-led decision-making?
Pietro Ameri
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Neurohormonal inhibition in CTRCD: preclinical and clinical evidence
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Modera
Peter van der Meer
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Modera
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Interviene en:
ATTR cardiac amyloidosis: recent therapeutic advances
Cristina Mitroi
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Interviene en:
Fibrilación auricular en cáncer activo ¿Cuándo pensar en control de ritmo?
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Modera
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Modera
Chiara Bucciarelli-Ducci
CARDIAC IMAGING IN CARDIO-ONCOLOGY. From findings to decisions
12 nov
Main auditorium
12:15 - 13:15
Interviene en:
CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls?
CARDIAC IMAGING IN CARDIO-ONCOLOGY. Smarter cardiac imaging pathways for patient-centred cardio-oncology care
12 nov
Main auditorium
16:15 - 17:00
Modera
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Modera
Dimitrios Farmakis
FROM BENCH TO BEDSIDE. The vicious cycle of cancer therapy–induced cardiac injury: mechanisms and treatment windows
12 nov
Main auditorium
15:20 - 16:15
Interviene en:
Reversible vs irreversible CTRCD: biological continuum or distinct entities?
IN FOCUS. Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
13 nov
Main auditorium
9:10 - 9:50
Modera
Sergio Cinza Sanjurjo
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Interviene en:
Alertas durante el tratamiento: cuándo actuar y cuándo derivar
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Interviene en:
Alertas ECG durante el tratamiento oncológico
Ejercicio y dieta, en pacientes con cáncer: guía rápida para Atención Primaria
12 nov
Room 1
16:45 - 17:15
Modera
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
MEET THE EXPERTS. Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
13 nov
Main auditorium
12:50 - 13:30
Modera
Vicente Pallarés Carratalá
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Modera
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Interviene en:
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Modera
Ana Martín García
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Interviene en:
Anticoagulación en CHA₂DS₂-VA bajo y en trombocitopenia
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Modera
Juan Pedro Justel
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Interviene en:
Panel discussion
Inauguración
12 nov
Room 1
13:50 - 14:00
Modera
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Interviene en:
Riesgo cardiovascular basal: qué identificar
Anticoagulación y manejo de arritmias en el paciente con cáncer
12 nov
Room 1
16:00 - 16:45
Modera
Cierre
12 nov
Room 1
17:45 - 17:55
Modera
Pilar Mazón Ramos
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Modera
CLINICAL CASE FORUM. Prevention and permissive cardiotoxicity: are we doing too much or too little?
13 nov
Main auditorium
16:00 - 17:00
Interviene en:
Albuminuria during VEGF inhibition: marker or mandate to act
Leticia Ruiz-Giménez
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Modera
Milagros Pedreira
Riesgo cardiovascular en pacientes con cáncer
12 nov
Room 1
14:00 - 14:45
Modera
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Interviene en:
Hipertensión asociada al tratamiento oncológico: objetivos realistas y seguros
Regina Dalmau
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Modera
Raquel de Paz Arias
IN FOCUS. Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy
12 nov
Main auditorium
11:45 - 12:15
Interviene en:
Panel discussion
Prevención cardiovascular más allá de la cardiotoxicidad
12 nov
Room 1
14:45 - 15:30
Modera
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Modera
Diego Jiménez Bou
Coordinación asistencial en cardio-oncología: del riesgo al seguimiento
12 nov
Room 1
17:15 - 17:45
Modera
SYMPOSIUM. Cardiovascular risk across cancer therapies and survivorship
13 nov
Main auditorium
8:30 - 9:10
Interviene en:
Cardiovascular risk with immunotherapy-based combinations
Antonia Sambola
CLINICAL CASE FORUM. Acute cardio-oncology: are we ready for the 24-hour challenge?
12 nov
Main auditorium
17:00 - 18:00
Modera
CLINICAL CASE FORUM. Vascular, valvular and metabolic challenges in patients with cancer
13 nov
Main auditorium
11:00 - 12:00
Modera
Rebeca Lorca Gutiérrez
FROM BENCH TO BEDSIDE. Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
13 nov
Main auditorium
12:00 - 12:50
Interviene en:
Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis
IN FOCUS. BTK inhibitors in CLL: new strategies, new cardiovascular questions
13 nov
Main auditorium
13:30 - 14:15
Modera
FILTRAR AGENDA
Resetear filtros
Tipo de sesión

II Jornada Cardiotox - SEMERGEN

Riesgo vascular y prevención cardiovascular en pacientes con cáncer

  • 12 noviembre 2026
  • 3.5 horas
  • Meeting Place Castellana 81, Madrid
  • Jornada en español
  • Descargar programa
REGISTRO
Coordinadores: 
  • Sergio Cinza, Centro de Salud Milladoiro, Santiago de Compostela
  • Juan Pedro Justel, Centro de Salud Universitario Dr. Castroviejo, Madrid
  • Vicente Pallares, Universidad Jaume I, Castellón
  • Teresa López-Fernández, Hospital Universitario La Paz, Madrid

Objetivo general:

Capacitar a los profesionales de atención primaria en la identificación, estratificación y manejo del riesgo cardiovascular (RCV) en pacientes con cáncer, antes, durante y después del tratamiento oncológico, reforzando la colaboración entre niveles asistenciales.

Objetivo específico:

Dotar de herramientas prácticas a los profesionales de atención primaria para detectar y manejar el RCV según la fase del proceso oncológico

¿Por qué esta jornada?

El aumento de la supervivencia en pacientes con cáncer plantea un nuevo reto asistencial: prevenir y tratar el riesgo cardiovascular asociado tanto a la enfermedad como a sus tratamientos. Los médicos de familia juegan un papel esencial para identificar precozmente a los pacientes en riesgo y garantizar un seguimiento coordinado y eficaz.

¿A quién va dirigida?

Equipos de atención primaria, residentes y cualquier profesional interesado en mejorar la atención cardiovascular de personas con cáncer.

¿Qué abordaremos?

En tres mesas breves y dinámicas, repasaremos las claves para:
🔹 Reconocer el riesgo cardiovascular desde la consulta de primaria
🔹 Actuar antes, durante y después del tratamiento oncológico
🔹 Coordinarse con oncología, hematología y cardiología a través de casos reales

Una jornada práctica, cercana y alineada con el futuro de la atención cardiovascular de excelencia al paciente con cáncer.

Programa de la II Jornada Cardiotox - SEMERGEN